About Supernus Pharmaceuticals, Inc.
https://www.supernus.comSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
CEO
Jack A. Khattar
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 197
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:10.39M
Value:$538.34M
BLACKROCK, INC.
Shares:8.7M
Value:$450.58M
VANGUARD GROUP INC
Shares:6.04M
Value:$313.12M
Summary
Showing Top 3 of 400
About Supernus Pharmaceuticals, Inc.
https://www.supernus.comSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $192.1M ▲ | $204M ▲ | $-45.12M ▼ | -23.49% ▼ | $-0.8 ▼ | $-36.6M ▼ |
| Q2-2025 | $165.45M ▲ | $136.49M ▼ | $22.5M ▲ | 13.6% ▲ | $0.4 ▲ | $33.5M ▲ |
| Q1-2025 | $149.82M ▼ | $144.32M ▲ | $-11.83M ▼ | -7.89% ▼ | $-0.21 ▼ | $17.79M ▼ |
| Q4-2024 | $174.16M ▼ | $126.66M ▲ | $15.33M ▼ | 8.8% ▼ | $0.28 ▼ | $45.23M ▼ |
| Q3-2024 | $175.69M | $117.26M | $38.5M | 21.91% | $0.7 | $65.05M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $281.16M ▼ | $1.42B ▲ | $370.09M ▲ | $1.05B ▼ |
| Q2-2025 | $522.6M ▲ | $1.38B ▲ | $318.5M ▲ | $1.06B ▲ |
| Q1-2025 | $463.59M ▲ | $1.35B ▼ | $316.58M ▼ | $1.03B ▼ |
| Q4-2024 | $453.61M ▲ | $1.37B ▲ | $332.34M ▼ | $1.04B ▲ |
| Q3-2024 | $403.21M | $1.34B | $335.55M | $1.01B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-45.12M ▼ | $-61.66M ▼ | $48.71M ▲ | $21.07M ▲ | $8.11M ▼ | $-61.79M ▼ |
| Q2-2025 | $22.5M ▲ | $58.53M ▲ | $-30.61M ▼ | $935K ▲ | $28.86M ▼ | $58.08M ▲ |
| Q1-2025 | $-11.83M ▼ | $30.6M ▼ | $37.32M ▲ | $-21.4M ▼ | $46.52M ▲ | $30.27M ▼ |
| Q4-2024 | $15.33M ▼ | $44.41M ▼ | $-12.64M ▲ | $5.89M ▲ | $37.66M ▲ | $44.19M ▼ |
| Q3-2024 | $38.5M | $53.52M | $-77.01M | $3.08M | $-20.42M | $53.32M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 APOKYN | $40.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Collaboration Revenue | $0 ▲ | $0 ▲ | $20.00M ▲ | $0 ▼ |
 GOCOVRI | $70.00M ▲ | $40.00M ▼ | $40.00M ▲ | $30.00M ▼ |
 Manufactured Product Other | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Oxtellar X R | $40.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Product | $330.00M ▲ | $160.00M ▼ | $170.00M ▲ | $140.00M ▼ |
 Qelbree | $130.00M ▲ | $80.00M ▼ | $80.00M ▲ | $60.00M ▼ |
 Royalty License And Other Revenue | $20.00M ▲ | $10.00M ▼ | $0 ▼ | $10.00M ▲ |
 Trokendi Xr | $30.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
CEO
Jack A. Khattar
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 197
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:10.39M
Value:$538.34M
BLACKROCK, INC.
Shares:8.7M
Value:$450.58M
VANGUARD GROUP INC
Shares:6.04M
Value:$313.12M
Summary
Showing Top 3 of 400